PI-05: PHARMACODYNAMIC EFFECTS OF AG-946, A HIGHLY POTENT NOVEL ACTIVATOR OF PYRUVATE KINASE, IN EX VIVO TREATMENT OF RED BLOOD CELLS FROM SICKLE CELL DISEASE PATIENTS

por M., RAB, M., VAN DIJK, J., BOS, B., VAN OIRSCHOT, J., GERRITS, P., KOSINSKI, C., KUNG, J., JANS, E., VAN BEERS, L., DANG, R., VAN WIJK
Publicado 2022

PI-02: FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE...

por M., VAN DIJK, M., RAB, B., VAN OIRSCHOT, J., BOS, C., DERICHS, A., RIJNEVELD, M., CNOSSEN, E., NUR, B., BIEMOND, M., BARTELS, J., JANS, W., VAN SOLINGE, R., SCHUTGENS, R., VAN WIJK, E., VAN BEERS
Publicado 2022

P-023: 2,3-DIPHOSPHOGLYCERATE DETECTION VIA DIRECT INFUSION HIGH RESOLUTION MASS SPECTROMETRY CORRELATES WITH QUANTITATIVE DETECTION IN BLOOD OF PATIENTS WITH SICKLE CELL DISEASE

por S., VAN DER VEEN, M., VAN DIJK, J., JANS, N., VERHOEVEN-DUIF, R., VAN WIJK, M., BARTELS, M., MAÑÚ PEREIRA, R., COLOMBATTI, M., MARTELLA, V., MUNARETO, M., BOARO, P., BARTOLLUCI, M., CNOSSEN, B., BIEMOND, E., VAN BEERS
Publicado 2022